longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Global X Genomics & Biotechnology ETF

GNOM

----
Start trading
OverviewOverviewNewsNewsPostsPostsWikiWikiRatingsRatingsCompositionCompositionDividendsDividends
LongbridgeAI
  • Revere Asset Management Inc Buys Shares of 26,620 Guardant Health, Inc. $GH

    Market Beat·7 hours ago
    GH+6.65%
  • BioMarin files Form 3 for director Robert M. Plenge, reporting no beneficial ownership

    PUBT·8 hours ago
    BMRN+1.11%
  • Guardant Health CIO Kumud Kalia disposes of 4,000 common shares worth $632,193.20

    PUBT·8 hours ago
    GH+6.65%
  • Moderna (NASDAQ:MRNA) CFO Sells $4,685,093.64 in Stock

    Market Beat·9 hours ago
    MRNA+1.89%MRNX+4.07%
  • Moderna CFO James M. Mock disposes of 34,836 common shares worth $4.68 million

    PUBT·10 hours ago
    MRNA+1.89%MRNX+4.07%
  • Intel Upgraded, CVS Health Downgraded: Updated Rankings on Top Blue-Chip Stocks

    InvestorPlace·13 hours ago
    - The author revised the Stock Grader recommendations for 93 major blue-chip stocks based on institutional buying pressure and fundamental health data. - Intel Corporation was upgraded to a strong rating, whereas CVS Health Corporation experienced a downgrade in its total evaluation. - Investors are encouraged to review these updated stock rankings and utilize the proprietary screening tool for profit opportunities.
    ILMN+0.85%ADI-4.69%
  • mRNA cancer vaccines’ biggest barriers to market

    biopharmadive·14 hours ago
    BNTX+2.20%MRK+0.64%
  • BioMarin Pharmaceutical (BMRN), What Is Behind The Fresh Attention?

    Simplywall·14 hours ago
    BMRN+1.11%
  • MRNA: Phase III melanoma success fuels expansion into new cancers, with scalable manufacturing and a strong vaccine portfolio

    Quartr·15 hours ago
    MRNA+1.89%MRNX+4.07%
  • Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types

    Market Beat·15 hours ago
    MRNA+1.89%MRNY+1.35%
  • This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy?

    Motley Fool·16 hours ago
    NTRA+3.91%
  • BioMarin Pharmaceutical Adds Independent Director to Board

    Tip Ranks·17 hours ago
    BMRN+1.11%
  • BioMarin appoints Bristol Myers Squibb research chief Robert Plenge to board

    PUBT·17 hours ago
    BMRN+1.11%
  • VRTX: Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead

    Quartr·18 hours ago
    VRTX+0.79%
  • Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead

    Market Beat·18 hours ago
    VRTX+0.79%